These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21415222)

  • 1. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors.
    Brodie A; Sabnis G
    Clin Cancer Res; 2011 Jul; 17(13):4208-13. PubMed ID: 21415222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance.
    Sabnis G; Brodie A
    Mol Cell Endocrinol; 2011 Jul; 340(2):142-7. PubMed ID: 20849912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
    Gilani RA; Kazi AA; Shah P; Schech AJ; Chumsri S; Sabnis G; Jaiswal AK; Brodie AH
    Breast Cancer Res Treat; 2012 Oct; 135(3):681-92. PubMed ID: 22878889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
    Brodie A; Njar V; Macedo LF; Vasaitis TS; Sabnis G
    Urol Oncol; 2009; 27(1):53-63. PubMed ID: 19111799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase, aromatase inhibitors, and breast cancer.
    Chumsri S; Howes T; Bao T; Sabnis G; Brodie A
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):13-22. PubMed ID: 21335088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G; Brodie A
    Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
    Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
    Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
    Wang SF; Chang YL; Tzeng YD; Wu CL; Wang YZ; Tseng LM; Chen S; Lee HC
    Cancer Lett; 2021 Dec; 523():82-99. PubMed ID: 34610415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
    Wong C; Wang X; Smith D; Reddy K; Chen S
    Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase resistance mechanisms in model systems in vivo.
    Brodie A; Macedo L; Sabnis G
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):283-7. PubMed ID: 19778610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
    Macedo LF; Sabnis G; Brodie A
    Cancer; 2008 Feb; 112(3 Suppl):679-688. PubMed ID: 18072255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
    Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
    Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
    Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.